CAMP4 Presents Translational Data from SYNGAP1-Related Disorders Program Showcasing Increased ...

CAMP4 Presents Translational Data from SYNGAP1-Related Disorders Program Showcasing Increased ...

Haploinsufficient SYNGAP1 mice treated with CMP-SYNGAP-01 demonstrated an increase in SYNGAP1 protein levels; treatment rescued multiple SYNGAP1-dependent behavioral phenotypes

CAMP4 presents translational data from SYNGAP1-related disorders program at ASGCT annual meeting - BioTuesdays

CAMP4 Therapeutics (NASDAQ:CAMP) has announced that three oral presentations on its SYNGAP1-related disorders and Urea Cycle Disorders (UCDs) programs, and shared favorable safety and pharmacokinetics data from the ongoing Phase 1 trial of CMP-CPS-001 in healthy volunteers, were delivered at the American Society of Gene and Cell Therapy (ASGCT) annual meeting, New Orleans, May 13 – 17, 2025. According to CAMP 4, the presentation included transla…